MIRD Pamphlet No. 29: MIRDy90-A Y Research Microsphere Dosimetry Tool

Overview

Journal J Nucl Med

Specialty Nuclear Medicine

Date 2024 Feb 22

PMID 38388514

Authors

Harry Marquis

Juan C Ocampo Ramos

Lukas M Carter

Pat Zanzonico

Wesley E Bolch

Richard Laforest

Adam L Kesner

Affiliations

Soon will be listed here.

Abstract

Y-microsphere radioembolization has become a well-established treatment option for liver malignancies and is one of the first U.S. Food and Drug Administration-approved unsealed radionuclide brachytherapy devices to incorporate dosimetry-based treatment planning. Several different mathematical models are used to calculate the patient-specific prescribed activity of Y, namely, body surface area (SIR-Spheres only), MIRD single compartment, and MIRD dual compartment (partition). Under the auspices of the MIRDsoft initiative to develop community dosimetry software and tools, the body surface area, MIRD single-compartment, MIRD dual-compartment, and MIRD multicompartment models have been integrated into a MIRDy90 software worksheet. The worksheet was built in MS Excel to estimate and compare prescribed activities calculated via these respective models. The MIRDy90 software was validated against available tools for calculating Y prescribed activity. The results of MIRDy90 calculations were compared with those obtained from vendor and community-developed tools, and the calculations agreed well. The MIRDy90 worksheet was developed to provide a vetted tool to better evaluate patient-specific prescribed activities calculated via different models, as well as model influences with respect to varying input parameters. MIRDy90 allows users to interact and visualize the results of various parameter combinations. Variables, equations, and calculations are described in the MIRDy90 documentation and articulated in the MIRDy90 worksheet. The worksheet is distributed as a free tool to build expertise within the medical physics community and create a vetted standard for model and variable management.

References

Ahmadzadehfar H, Sabet A, Biermann K, Muckle M, Brockmann H, Kuhl C . The significance of 99mTc-MAA SPECT/CT liver perfusion imaging in treatment planning for 90Y-microsphere selective internal radiation treatment. J Nucl Med. 2010; 51(8):1206-12. DOI: 10.2967/jnumed.109.074559. View

Dezarn W, Cessna J, DeWerd L, Feng W, Gates V, Halama J . Recommendations of the American Association of Physicists in Medicine on dosimetry, imaging, and quality assurance procedures for 90Y microsphere brachytherapy in the treatment of hepatic malignancies. Med Phys. 2011; 38(8):4824-45. DOI: 10.1118/1.3608909. View

Thomas M, Mahvash A, Abdelsalam M, Kaseb A, Kappadath S . Planning dosimetry for Y radioembolization with glass microspheres: Evaluating the fidelity of Tc-MAA and partition model predictions. Med Phys. 2020; 47(10):5333-5342. DOI: 10.1002/mp.14452. View

Struycken L, Patel M, Kuo P, Hennemeyer C, Woodhead G, McGregor H . Clinical and Dosimetric Implications of Calculating Lung Shunt Fraction for Hepatic Y Radioembolization Using SPECT/CT Versus Planar Scintigraphy. AJR Am J Roentgenol. 2021; 218(4):728-737. DOI: 10.2214/AJR.21.26663. View

Elsayed M, Cheng B, Xing M, Sethi I, Brandon D, Schuster D . Comparison of Tc-99m MAA Planar Versus SPECT/CT Imaging for Lung Shunt Fraction Evaluation Prior to Y-90 Radioembolization: Are We Overestimating Lung Shunt Fraction?. Cardiovasc Intervent Radiol. 2020; 44(2):254-260. DOI: 10.1007/s00270-020-02638-8. View

Villalobos A, Soliman M, Majdalany B, Schuster D, Galt J, Bercu Z . Yttrium-90 Radioembolization Dosimetry: What Trainees Need to Know. Semin Intervent Radiol. 2020; 37(5):543-554. PMC: 7732571. DOI: 10.1055/s-0040-1720954. View

Kim C, Yeom Y, Petoussi-Henss N, Zankl M, Bolch W, Lee C . ICRP Publication 145: Adult Mesh-Type Reference Computational Phantoms. Ann ICRP. 2020; 49(3):13-201. DOI: 10.1177/0146645319893605. View

Moran V, Prieto E, Sancho L, Rodriguez-Fraile M, Soria L, Zubiria A . Impact of the dosimetry approach on the resulting Y radioembolization planned absorbed doses based on Tc-MAA SPECT-CT: is there agreement between dosimetry methods?. EJNMMI Phys. 2020; 7(1):72. PMC: 7721939. DOI: 10.1186/s40658-020-00343-6. View

Garin E, Rolland Y, Laffont S, Edeline J . Clinical impact of (99m)Tc-MAA SPECT/CT-based dosimetry in the radioembolization of liver malignancies with (90)Y-loaded microspheres. Eur J Nucl Med Mol Imaging. 2015; 43(3):559-75. PMC: 4731431. DOI: 10.1007/s00259-015-3157-8. View

10.

Lau W, Kennedy A, Kim Y, Lai H, Lee R, Leung T . Patient selection and activity planning guide for selective internal radiotherapy with yttrium-90 resin microspheres. Int J Radiat Oncol Biol Phys. 2010; 82(1):401-7. DOI: 10.1016/j.ijrobp.2010.08.015. View

11.

Salem R, Thurston K . Radioembolization with yttrium-90 microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: part 3: comprehensive literature review and future direction. J Vasc Interv Radiol. 2006; 17(10):1571-93. DOI: 10.1097/01.RVI.0000236744.34720.73. View

12.

Kafrouni M, Allimant C, Fourcade M, Vauclin S, Guiu B, Mariano-Goulart D . Analysis of differences between Tc-MAA SPECT- and Y-microsphere PET-based dosimetry for hepatocellular carcinoma selective internal radiation therapy. EJNMMI Res. 2019; 9(1):62. PMC: 6646451. DOI: 10.1186/s13550-019-0533-6. View

13.

Georgiou M, Kuker R, Studenski M, Ahlman P, Witte M, Portelance L . Lung shunt fraction calculation using Tc-MAA SPECT/CT imaging for Y microsphere selective internal radiation therapy of liver tumors. EJNMMI Res. 2021; 11(1):96. PMC: 8479035. DOI: 10.1186/s13550-021-00837-z. View

14.

Van B, Dewaraja Y, Sangogo M, Mikell J . Y-90 SIRT: evaluation of TCP variation across dosimetric models. EJNMMI Phys. 2021; 8(1):45. PMC: 8192668. DOI: 10.1186/s40658-021-00391-6. View

15.

Riveira-Martin M, Akhavanallaf A, Mansouri Z, Wolf N, Salimi Y, Ricoeur A . Predictive value of Tc-MAA-based dosimetry in personalized Y-SIRT planning for liver malignancies. EJNMMI Res. 2023; 13(1):63. PMC: 10317941. DOI: 10.1186/s13550-023-01011-3. View

16.

Ibrahim S, Lewandowski R, Sato K, Gates V, Kulik L, Mulcahy M . Radioembolization for the treatment of unresectable hepatocellular carcinoma: a clinical review. World J Gastroenterol. 2008; 14(11):1664-9. PMC: 2695906. DOI: 10.3748/wjg.14.1664. View

17.

Dieudonne A, Sanchez-Garcia M, Bando-Delaunay A, Lebtahi R . Concepts and methods for the dosimetry of radioembolisation of the liver with Y-90-loaded microspheres. Front Nucl Med. 2024; 2:998793. PMC: 11464973. DOI: 10.3389/fnume.2022.998793. View

18.

Smits M, Elschot M, Sze D, Kao Y, Nijsen J, Iagaru A . Radioembolization dosimetry: the road ahead. Cardiovasc Intervent Radiol. 2014; 38(2):261-9. DOI: 10.1007/s00270-014-1042-7. View

19.

Kao Y, Tan E, Ng C, Goh S . Clinical implications of the body surface area method versus partition model dosimetry for yttrium-90 radioembolization using resin microspheres: a technical review. Ann Nucl Med. 2011; 25(7):455-61. DOI: 10.1007/s12149-011-0499-6. View

20.

Dodson C, Marshall C, Durieux J, Wojtylak P, Davidson J, Muzic R . Using an Assumed Lung Mass Inaccurately Estimates the Lung Absorbed Dose in Patients Undergoing Hepatic Yttrium Radioembolization Therapy. Cardiovasc Intervent Radiol. 2022; 45(12):1793-1800. DOI: 10.1007/s00270-022-03197-w. View